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Reducing risks from coronavirus transmission in the
home—the role of viral load
Paul Little and colleagues call for better promotion of simple measures that can help reduce the
spread and severity of infection among those living with people who have covid-19
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Most people with covid-19 are cared for at home, increasing
the likely exposure of household members. Although the
evidence is limited, high infection rates among health workers
have been attributed to more frequent contact with infected
patients, and higher viral load —the size of the infecting dose
of virus. This has led to demands for better personal protection
equipment (PPE). Less attention, however, has been given to
family members and others caring for people with covid-19 in
the community. Providing them with the same level of PPE as
in hospitals is not practicable, but promotion of simple evidence
based interventions may lower the risk of infection transmission
and help reduce morbidity and demand on hospitals.
Transmission in home and community
The long incubation and high presymptomatic infectivity of
covid-19 makes transmission between family members a
particular risk. Modelling of viral shedding in 94 patients with
covid-19 and 77 transmission pairs suggests that the highest
viral load is at or just before symptom onset, with 44% of
transmission occurring before symptoms.1
Public health advice recommends isolation of symptomatic
household members, but this can be difficult, particularly in
small flats with shared facilities. Motivation to overcome these
difficulties may not be high enough if members of the public
are sceptical about reducing transmission in the home and
unaware that the illness of other family members may be more
severe if they do not reduce their level of exposure.
The medical community is commendably reluctant to make
recommendations in the absence of evidence. An expert team
that reviewed the evidence for viral load concluded that until
the evidence is more conclusive: “As our grandfathers used to
say, when you do not know what is going on, do nothing.”2
However, given that measures to reduce the viral load from
exposure to symptomatic household members have little risk
of harm, the precautionary principle suggests that we should be
promoting them. It is difficult to get good dose-response data,
but it seems prudent not to treat absence of direct evidence in
the pandemic as evidence of absence, particularly given evidence
from other viral infections from both animal and human models,
and trial evidence for reducing the transmission among families
in non-pandemic years. Greater awareness of the potential risk
from viral load may help motivate family members to pay
sufficient attention to protecting themselves despite their concern
for sick family members.
Evidence for viral load effect
It is intuitive that viral load should influence the incidence and
severity of disease. The main problem is that measuring the
viable infecting dose of the virus in people is extremely
challenging: contemporary measures of viral density, viability,
and viral contamination are all hard to obtain. Establishing the
relation between infecting dose and the likelihood of developing
disease is therefore difficult.
The challenge of establishing the infecting dose is complicated
by environmental contamination. Experience with Middle East
respiratory syndrome (MERS), caused by another coronavirus
(MERS-CoV), suggests that environmental contamination with
SARS-CoV-2 is likely to be high,3 and this is supported by
recent case reports of extensive environmental contamination
from patients with covid-19.4 Indirect evidence, including from
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animal models and epidemiological studies also provides
support.
Animal models
Although the infecting dose from a combination of droplets and
environmental contamination cannot be easily measured, high
quality experiments under controlled conditions in animal
models can provide indirect evidence. We are not aware of
infecting dose experiments with animal models of covid-19,
but animal models of other viral infections show that variation
in the infecting dose determines how many animals get infected
and how severe the illness is.
A model of African swine flu virus shows a clear dose-response
relation between the infecting dose and disease in the animal.5 6
Likewise, a strong dose-response effect is found in the animal
model for haemopoietic necrosis virus.6 A dose-response has
also been shown in mouse models with several strains of
SARS-CoV-1, which is closely related the virus causing
covid-19 (SARS-CoV-2). The infectivity varies between
different strains of the virus, which modifies the shape of the
dose-response curve, but nevertheless consistent dose-response
relations are observed with the severity of the infection.7 8
Defective viral genomes
One of the key factors in determining how severe an infection
becomes is also the extent to which defective viral genomes are
produced. These effectively reduce the infecting doses during
the early part of an infection by competing with non-defective
genomes.9 The greater the abundance of viruses with defective
genomes within an infecting inoculum, the better the clinical
outcome10: genomic analysis of viruses isolated from previously
healthy people requiring admission to the intensive care unit
with influenza A infection, those not requiring intensive care,
and those who died (who also had underlying medical
conditions) showed that defective genomes were associated
with fewer severe or fatal outcomes.
Epidemiology of serious viral infections
The evidence from other similar serious viral infections also
suggests the infecting viral load may be important. A
retrospective study of survivors of Ebola from the Kerry Town
treatment centre in Sierra Leone, investigated disease in more
than 933 family members (those who had died, those surviving,
and those not infected). The severity of infecting dose was
graded according to the history of exposure. Although there was
no clear relation with mortality, perhaps because of the
mediating effect of treatment at the treatment centre, the study
found a very strong linear relation with the likelihood of
infection developing, ranging from 80% likelihood of getting
the disease with the highest infecting dose (direct contact with
body of someone who had died) and 10% with the lowest dose
(no contact).11
During the 2003 SARS outbreak older age, comorbidities
(adjusted hazard ratio (HR) 3.36, 95% confidence interval 1.44
to 7.82), and higher initial viral levels in nasopharyngeal
specimens (adjusted HR 1.21 per log10 increase in number of
RNA copies/mL, 95% CI 1.06 to 1.39) were associated with
worse survival.12 Viral level 10 days after the onset of symptoms
was associated with a series of poor clinical markers (oxygen
desaturation, mechanical ventilation) and death.13 Recent data
from covid-19 have shown that those with severe infections had
viral levels 60 times higher at presentation than those with mild
disease.14 Although the levels of virus once the disease has
started will be in part a function of the immune response of the
patient, the size of the initial viral load is likely to be a
contributing factor, allowing immune defences to be more easily
over-run.
The difference in case fatality rates in the three waves of the
Spanish flu pandemic of 1918-19 can be explained by the
number of simultaneous contacts a susceptible person had with
infected people (the more contact the higher the infectious
doses).15 However, in a detailed study modelling influenza virus
transmission within households in 2008-12, infectivity was
proportional to viral load but viral load alone provided a poor
fit to the models.16 Clearly we need to better understand the
relation between infecting dose and other prognostic factors in
modifying the immune response and clinical outcome (age,
comorbidity, etc).
Pragmatic evidence that could help carers
We are aware of only one behavioural intervention that is proved
to reduce virus transmission within households and is suitable
for rapid dissemination in a pandemic. Two of us (PL and LY)
were involved in a randomised trial of Germ Defence, a website
that provides advice on infection control measures and helps
users think about when and how to carry out key infection
control behaviours such as handwashing and cleaning, avoiding
sharing rooms and surfaces, managing incoming deliveries, and
ventilating rooms.17 This could supplement public health advice
on infection control in the home since it uses behaviour change
techniques to help people implement this advice (box 1).
Box 1: Behaviour change techniques to reduce virus
transmission
• Explaining the importance and benefits of reducing exposure to motivate
users to restrict their exposure
• Planning how to isolate an infected household member as far as possible
(eg, by avoiding sharing areas of the home)
• Personalised goal setting to increase infection control behaviours
• Changing the home environment to support new habits (eg, improving
ventilation and increasing protective behaviours such as cleaning shared
surfaces)
• Problem solving to overcome barriers
Germ Defence was trialled in 20 066 people during the H1N1
pandemic and subsequent seasonal flu years17 and reduced the
number of respiratory infections (mean number of infections
0.84 v l.09 in the control group, hazard ratio 0.75, 95%
confidence intervals 0.72 to 0.79). Infection transmission among
family members was lower in the intervention group (hazard
ratio 0.79, 95% confidence interval 0.74 to 0.83), and there was
a modest reduction in severity of infections (mean number of
days of moderately bad illness 3.9 (median 2 days) in
intervention versus 4.5 (3) days in the control group). Reductions
were also observed in gastrointestinal infections, GP
consultations, and antibiotic prescriptions.
The team has been funded by UK Research and Innovation to
adapt this intervention for covid-19 and disseminate it nationally
and internationally. It has already been translated into over 20
languages for this purpose (see www.germdefence.org/). Germ
Defence may help limit transmission of covid-19 as well as the
other viruses that are still causing the majority of respiratory
illnesses in the current pandemic, even in secondary care
settings.18 Other viruses may also be important given recent
evidence that coinfection with other viruses occurs in more than
20% of cases.19
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Care is needed when extrapolating evidence from other disease,
but viral load is likely to be important for covid-19. The
precautionary principle suggests that people caring for household
members who are unwell should be encouraged to take measures
to reduce infecting viral load in order to reduce the incidence
and severity of infection. Promoting infection control measures
in the community is a priority for the UK government and will
continue to be so as “stay at home” policies are lifted.
Dissemination of evidence based behavioural interventions may
help increase adoption of public health advice and reduce viral
load.
Key messages
Government policy is aimed at reducing transmission of covid-19 between
family units, but less attention has been given to transmission between
family members
Evidence from controlled experiments in animal models, viral genome
studies, and other epidemics suggests the infecting viral load may be
important
A web based intervention has been shown to reduce incidence,
transmission, and severity of seasonal flu
Use of such behavioural interventions could support public health advice
to improve infection control in families
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